HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Guoquan Food (Shanghai) - High Growth May Not Be Sustainable; Long Logic Doesn't Hold Water

China Healthcare Weekly (Oct.13) - Deteriorating Financing Environment, ADC>BsAb>CGT, Fosun Pharma

GLP-1 Drugs – Are They Dessert or Time Bomb to Your Portfolio?

China's Weight Loss Drug Market – The Investment Opportunities and the Risks Behind

Wuxi Biologics (2269.HK) 23H1 - The Positives, the Negatives and the Outlook

WuXi AppTec (2359.HK/603259.CH) 23H1 - Is It Time to Start Being Optimistic?

China Traditional Chinese Medicine (570.HK) - The Privatization Rumor and the Outlook

Equity Bottom-Up

<ul>
<li>WuXi AppTec's share price has performed well recently, mainly driven by CXO's "immune attributes" to anti-corruption campaign, investors' bullish view of weight loss drug business, and the previous oversold rebound.</li>
<li>Peptide CDMO business would contribute limited incremental performance to WuXi AppTec considering overall large business volume.Downward trend of CRO business is hard to be hedged by weight loss drug business.</li>
<li>Due to higher-for-longer rate, China CXOs only have rebound value, but no reversal logic. It's time to consider taking profits in a timely manner before the share price falls again.</li>
</ul>


WuXi AppTec's share price has performed well recently, mainly driven by CXO's "immune attributes" to anti-corruption campaign, investors' bullish view of weight loss drug business, and the previous oversold rebound.
Peptide CDMO business would contribute limited incremental performance to WuXi AppTec considering overall large business volume.Downward trend of CRO business is hard to be hedged by weight loss drug business.
Due to higher-for-longer rate, China CXOs only have rebound value, but no reversal logic. It's time to consider taking profits in a timely manner before the share price falls again.


WuXi AppTec (2359.HK/603259.CH) - Would the Recent Rebound in Share Price Be a Flash in the Pan?